In connection with the start of the phase 3 trials of PCV21, Sanofi has expanded its alliance with South Korea-based SK Bio, ...

SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in ...

Respiratory virus season has arrived, and hopefully you’re up to date on vaccinations that can help prevent infectious diseases including COVID, the flu, whooping cough, and respiratory syncytial ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

PCV21 is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter a Phase III clinical trial in infants and toddlers. Sanofi and SK Bioscience announced that they have ...

Anticipated growth for ‘Saudi Arabia 23 Valent Pneumococcal Polysaccharide Vaccine Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising ...

With temperatures dipping across Northern Ireland, experts are urging people to take extra precautions to stay healthy.

The following is a summary of “A nationwide study of two decades of invasive pneumococcal disease in the Faroe Islands, ...

Hailsham Town Council has issued some guidance to residents on how to stay healthy and warm during the colder winter months, ...

The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.